Status: Not yet recruiting
TH-CAR-027 for Grade 4 Gliomas
This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive grade 4 glioma
Participants needed: 21
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Tongji Hospital, Tongji University School of MedicineUpdated: Feb 4, 2026
Eligibility criteria
1. Voluntarily participate in the clinical trial; fully understand and are infor... [+4]
Seropositivity for HIV antibody or positive serological test for Treponema palli... [+11]